Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms

This article was originally published in The Pink Sheet Daily

Executive Summary

Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.

You may also be interested in...



GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds

Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.

GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds

Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.

La Jolla Submits Riquent Application For Lupus In EU

The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel